337 related articles for article (PubMed ID: 11850790)
1. Oligonucleotide N3'-->P5' phosphoramidates as efficient telomerase inhibitors.
Herbert BS; Pongracz K; Shay JW; Gryaznov SM
Oncogene; 2002 Jan; 21(4):638-42. PubMed ID: 11850790
[TBL] [Abstract][Full Text] [Related]
2. Oligonucleotide n3'-->p5' phosphoramidates and thio-phoshoramidates as potential therapeutic agents.
Gryaznov SM
Chem Biodivers; 2010 Mar; 7(3):477-93. PubMed ID: 20232321
[TBL] [Abstract][Full Text] [Related]
3. Oligonucleotide N3' --> P5' thio-phosphoramidate telomerase template antagonists as potential anticancer agents.
Gryaznov S; Asai A; Oshima Y; Yamamoto Y; Pongracz K; Pruzan R; Wunder E; Piatyszek M; Li S; Chin A; Harley C; Akinaga S; Yamashita Y
Nucleosides Nucleotides Nucleic Acids; 2003; 22(5-8):577-81. PubMed ID: 14565232
[TBL] [Abstract][Full Text] [Related]
4. Lipid modification of GRN163, an N3'-->P5' thio-phosphoramidate oligonucleotide, enhances the potency of telomerase inhibition.
Herbert BS; Gellert GC; Hochreiter A; Pongracz K; Wright WE; Zielinska D; Chin AC; Harley CB; Shay JW; Gryaznov SM
Oncogene; 2005 Aug; 24(33):5262-8. PubMed ID: 15940257
[TBL] [Abstract][Full Text] [Related]
5. Telomerase inhibitors--oligonucleotide phosphoramidates as potential therapeutic agents.
Gryaznov S; Pongracz K; Matray T; Schultz R; Pruzan R; Aimi J; Chin A; Harley C; Shea-Herbert B; Shay J; Oshima Y; Asai A; Yamashita Y
Nucleosides Nucleotides Nucleic Acids; 2001; 20(4-7):401-10. PubMed ID: 11563055
[TBL] [Abstract][Full Text] [Related]
6. A novel telomerase template antagonist (GRN163) as a potential anticancer agent.
Asai A; Oshima Y; Yamamoto Y; Uochi TA; Kusaka H; Akinaga S; Yamashita Y; Pongracz K; Pruzan R; Wunder E; Piatyszek M; Li S; Chin AC; Harley CB; Gryaznov S
Cancer Res; 2003 Jul; 63(14):3931-9. PubMed ID: 12873987
[TBL] [Abstract][Full Text] [Related]
7. Telomerase targeted oligonucleotide thio-phosphoramidates in T24-luc bladder cancer cells.
Dikmen ZG; Wright WE; Shay JW; Gryaznov SM
J Cell Biochem; 2008 May; 104(2):444-52. PubMed ID: 18044713
[TBL] [Abstract][Full Text] [Related]
8. Oligonucleotide conjugate GRN163L targeting human telomerase as potential anticancer and antimetastatic agent.
Gryaznov SM; Jackson S; Dikmen G; Harley C; Herbert BS; Wright WE; Shay JW
Nucleosides Nucleotides Nucleic Acids; 2007; 26(10-12):1577-9. PubMed ID: 18066830
[TBL] [Abstract][Full Text] [Related]
9. Effects of oligonucleotide N3'-->P5' thio-phosphoramidate (GRN163) targeting telomerase RNA in human multiple myeloma cells.
Akiyama M; Hideshima T; Shammas MA; Hayashi T; Hamasaki M; Tai YT; Richardson P; Gryaznov S; Munshi NC; Anderson KC
Cancer Res; 2003 Oct; 63(19):6187-94. PubMed ID: 14559802
[TBL] [Abstract][Full Text] [Related]
10. Effects of a novel telomerase inhibitor, GRN163L, in human breast cancer.
Gellert GC; Dikmen ZG; Wright WE; Gryaznov S; Shay JW
Breast Cancer Res Treat; 2006 Mar; 96(1):73-81. PubMed ID: 16319992
[TBL] [Abstract][Full Text] [Related]
11. Novel short oligonucleotide conjugates as inhibitors of human telomerase.
Pongracz K; Li S; Herbert BS; Pruzan R; Wunder E; Chin A; Piatyszek M; Shay J; Gryaznov SM
Nucleosides Nucleotides Nucleic Acids; 2003; 22(5-8):1627-9. PubMed ID: 14565482
[TBL] [Abstract][Full Text] [Related]
12. In vivo inhibition of lung cancer by GRN163L: a novel human telomerase inhibitor.
Dikmen ZG; Gellert GC; Jackson S; Gryaznov S; Tressler R; Dogan P; Wright WE; Shay JW
Cancer Res; 2005 Sep; 65(17):7866-73. PubMed ID: 16140956
[TBL] [Abstract][Full Text] [Related]
13. Antiadhesive effects of GRN163L--an oligonucleotide N3'->P5' thio-phosphoramidate targeting telomerase.
Jackson SR; Zhu CH; Paulson V; Watkins L; Dikmen ZG; Gryaznov SM; Wright WE; Shay JW
Cancer Res; 2007 Feb; 67(3):1121-9. PubMed ID: 17283146
[TBL] [Abstract][Full Text] [Related]
14. Allosteric inhibitors of telomerase: oligonucleotide N3'-->P5' phosphoramidates.
Pruzan R; Pongracz K; Gietzen K; Wallweber G; Gryaznov S
Nucleic Acids Res; 2002 Jan; 30(2):559-68. PubMed ID: 11788719
[TBL] [Abstract][Full Text] [Related]
15. RNA mimetics: oligoribonucleotide N3'-->P5' phosphoramidates.
Gryaznov SM; Winter H
Nucleic Acids Res; 1998 Sep; 26(18):4160-7. PubMed ID: 9722635
[TBL] [Abstract][Full Text] [Related]
16. Telomerase inhibitors and 'T-oligo' as cancer therapeutics: contrasting molecular mechanisms of cytotoxicity.
Rankin AM; Faller DV; Spanjaard RA
Anticancer Drugs; 2008 Apr; 19(4):329-38. PubMed ID: 18454043
[TBL] [Abstract][Full Text] [Related]
17. alpha-Oligodeoxyribonucleotide N3'-->P5' phosphoramidates: synthesis and duplex formation.
Pongracz K; Gryaznov SM
Nucleic Acids Res; 1998 Feb; 26(4):1099-106. PubMed ID: 9461474
[TBL] [Abstract][Full Text] [Related]
18. Antitumor effects of specific telomerase inhibitor GRN163 in human glioblastoma xenografts.
Ozawa T; Gryaznov SM; Hu LJ; Pongracz K; Santos RA; Bollen AW; Lamborn KR; Deen DF
Neuro Oncol; 2004 Jul; 6(3):218-26. PubMed ID: 15279714
[TBL] [Abstract][Full Text] [Related]
19. Oligonucleotide N3'-->P5' phosphoramidates as antisense agents.
Gryaznov S; Skorski T; Cucco C; Nieborowska-Skorska M; Chiu CY; Lloyd D; Chen JK; Koziolkiewicz M; Calabretta B
Nucleic Acids Res; 1996 Apr; 24(8):1508-14. PubMed ID: 8628685
[TBL] [Abstract][Full Text] [Related]
20. Overcoming the immortality of tumour cells by telomere and telomerase based cancer therapeutics--current status and future prospects.
Kelland LR
Eur J Cancer; 2005 May; 41(7):971-9. PubMed ID: 15862745
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]